Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21451908 | 0.91 | LMNA (0.42) | LMNAPOLBP2RX7HDAC4SCN9A | |
| SCHEMBL22727639 | 0.91 | LMNA (0.42) | LMNAPOLBP2RX7HDAC4SCN9A | |
| SCHEMBL21452175 | 0.89 | HDAC4 (0.39) | P2RX7HDAC4SCN9ADDB1CRBN | |
| SCHEMBL21452206 | 0.87 | DRD2 (0.35) | LMNAP2RX7HDAC4DDB1CRBN | |
| SCHEMBL21452195 | 0.87 | SCN9A (0.35) | EPHX2SCN9ADDB1CRBNRORC | |
| SCHEMBL21452470 | 0.87 | SCN9A (0.35) | EPHX2SCN9ADDB1CRBNRORC | |
| SCHEMBL21452471 | 0.87 | SCN9A (0.35) | EPHX2SCN9ADDB1CRBNRORC | |
| SCHEMBL21452482 | 0.86 | SCN9A (0.40) | LMNAPOLBP2RX7HDAC4SCN9A | |
| SCHEMBL21452238 | 0.84 | DPP8 (0.37) | LMNAPOLBEPHX2P2RX7SCN9A | |
| SCHEMBL21452201 | 0.84 | HDAC4 (0.41) | LMNAPOLBTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171487-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JIANHE PHARMACEUTICAL & TECHNOLOGY CO. LTD. (CN) | 2021-06-10 | — | — | US | disclosed |
| EP-3778579-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jianhe Pharmaceutical & Technology Co. Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019192602-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海键合医药科技有限公司 | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171487-A1 | AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, PAH, COMT | LMNA 3431/4885POLB 4108/4885TAS1R3 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.